Orchestra BioMed Holdings (OBIO) EBITDA Margin (2022 - 2026)
Orchestra BioMed Holdings (OBIO) reported EBITDA Margin of 18900.91% for Q1 2026, down 1673847.0% year-over-year from N/an in Q1 2025, and down 93448.15% on a QoQ basis from 20.25% in Q4 2025.
Orchestra BioMed Holdings (OBIO) has 5 years of EBITDA Margin data on file, last reported at 18900.91% in Q1 2026.
- Quarterly EBITDA Margin fell 1673847.0% year-over-year to 18900.91% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 167.2% (up 212909.0% YoY) and the FY2025 annual result came in at 157.38%, up 215354.0% from the prior year.
- EBITDA Margin slipped to 18900.91% in Q1 2026 per OBIO's latest filing, from 20.25% in the prior quarter.
- Across five years, EBITDA Margin topped out at 20.25% in Q4 2025 and bottomed at 18900.91% in Q1 2026.
- The 5-year median for EBITDA Margin is 2055.91% (2024), against an average of 3097.15%.
- The widest annual swing landed in 2025, when EBITDA Margin jumped 642381 bps; it then tumbled 1673847 bps in 2026.
- Tracing OBIO's EBITDA Margin over 5 years: stood at 884.68% in 2022, then sank by 450 bps to 4866.79% in 2023, then tumbled by 32 bps to 6403.56% in 2024, then surged by 100 bps to 20.25% in 2025, then slumped by 93448 bps to 18900.91% in 2026.
- Per Business Quant, the three latest OBIO EBITDA Margin figures stand at 18900.91% (Q1 2026), 20.25% (Q4 2025), and 2415.68% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 18.35% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 17.24% |
| 10 | Orchestra BioMed Holdings | 245.24 Mn | 255.02 Mn | 78,000.00 | -18,900.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18,900.91% |
| Dec 31, 2025 | 20.25% |
| Sep 30, 2025 | -2,415.68% |
| Jun 30, 2025 | -2,318.66% |
| Mar 31, 2025 | -2,162.44% |
| Dec 31, 2024 | -6,403.56% |
| Sep 30, 2024 | -1,550.66% |
| Jun 30, 2024 | -2,055.91% |
| Mar 31, 2024 | -2,171.13% |
| Dec 31, 2023 | -4,866.79% |
| Sep 30, 2023 | -3,173.51% |
| Jun 30, 2023 | -1,323.17% |
| Mar 31, 2023 | -942.18% |
| Dec 31, 2022 | -884.68% |
| Sep 30, 2022 | -884.09% |
| Jun 30, 2022 | -1,956.86% |
| Mar 31, 2022 | -661.55% |